TrialOncoimmunology2024

A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12).

Dong Ki Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.